Medicenna Therapeutics (TSE:MDNA) Given “Buy” Rating at Brookline Capital Management

Brookline Capital Management restated their buy rating on shares of Medicenna Therapeutics (TSE:MDNA) in a research report sent to investors on Tuesday, BayStreet.CA reports. They currently have a C$4.00 price objective on the stock.

TSE MDNA traded down C$0.01 during trading on Tuesday, reaching C$1.69. The company’s stock had a trading volume of 129,196 shares, compared to its average volume of 40,611. The firm has a fifty day moving average of C$1.30 and a 200 day moving average of C$1.25. Medicenna Therapeutics has a one year low of C$0.64 and a one year high of C$2.38. The stock has a market capitalization of $59.01 million and a PE ratio of -7.67.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors.

Featured Article: Why do companies issue monthly dividends?

Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.